[ad_1]
Ondine Biomedical’s Steriwave Nasal Photodisinfection
Vancouver, Canada, May 4, 2020 (GLOBE NEWSWIRE) – Vancouver-based Ondine Biomedical Inc., the world leader in photodisinfection technology, announces that it has received CE Mark approval for its broad-spectrum non-antibiotic nasal decolonization therapy spectrum.
“The nose is an important reservoir of bacteria, fungi and viruses that can cause serious hospital infections in the ICU or after surgery when the immune system of patients weakens,” said Dr. Roger Andersen, vice president of medical affairs and Ondine Regulatory. “Steriwave nasal photodisinfection is able to eliminate pathogens that cause infection of the nose of patients with a single, quick and painless treatment. When used before surgery, nasal photodisinfection has reduced infections by 80% from the surgical site. “
“We are excited to be able to bring our photodisinfection technology to patients in the European Union,” said Tom Dawson, Vice President of Engineering and Operations. “This is especially important during these unprecedented times, when minimizing complications from surgeries and hospital stays can improve patient outcomes and reduce the burden on overloaded health systems.”
About photodisinfection
Ondine photodisinfection is a powerful new alternative in the fight against drug-resistant topical infections. This patented, light-activated antimicrobial kills drug-resistant bacteria, viruses, and fungi, including biofilm, in minutes. Because photodisinfection is effective against such a broad spectrum of pathogens, expensive and time-consuming identification is not required. Photodisinfection kills pathogens through oxidative disruption with no known adverse effects on human epithelial tissue or mucosa. Microbes cannot resist or adapt to this treatment.
About Steriwave ™ Nasal Decolonization
Ondine’s primary product is Steriwave ND, a photodisinfection-based treatment that can kill nasal bacteria, viruses, and fungi in symptomatic and asymptomatic carriers to reduce the potential for transmission and infection. Steriwave ND involves a 6-minute treatment implemented just before surgery that does not generate resistance with multiple use. The patient’s own nose has been shown to be a primary source of pathogens involved in hospital-acquired infections, including MRSA. Carriers of bacteria, viruses, and fungi in their noses are at increased risk of self-infection and represent a vector of transmission to others. The adoption of Ondine’s universal presurgical nasal decolonization protocols in Canadian hospitals over the past decade has resulted in significant reductions in surgical site infections. Steriwave is not available in the US. USA
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a certified women-owned company dedicated to the development of preventive treatments and therapies for a broad spectrum of multi-drug resistant bacterial, viral, and fungal infections. Ondine’s antimicrobial program uses photodisinfection (also known as antimicrobial photodynamic therapy, or aPDT) to provide rapid antimicrobial efficacy without increasing the risk of resistance. In addition to Steriwave ND, other applications of the photodisinfection platform are being developed, including the treatment of chronic rhinosinusitis, the treatment of burns and wounds, the disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and, more recently , the development of topical antivirals. therapy for the upper respiratory tract to reduce the transmission of SARS-CoV-2.
-
Steriwave Nasal photodisinfection
Angelika Vance Ondine Biomedical Inc. 6048382702 [email protected]
